Jonathan Davies
`Partner
`
`jdavies@cooley.com
`
`+1 202 776 2049
`
`Washington, DC
`
`Intellectual Property Litigation
`Life Sciences IP Litigation
`Intellectual Property
`
`Dr. Jonathan Davies’ practice focuses on patent litigation with an emphasis on pharmaceutical and
`biotechnology cases, including Hatch-Waxman litigation related to Abbreviated New Drug Applications
`(ANDAs) and biologics litigation under the Biologics Price Competition and Innovation Act (BPCIA).
`
`Jonathan’s litigation experience includes all aspects of pre-trial and trial district court practice. He also has
`experience advising clients in infringement and validity opinions.
`
`Prior to law school, Jonathan completed graduate studies in human physiology and conducted doctoral and
`post-doctoral research in cellular and molecular biology and genetics. His research focused on molecular
`mechanisms that regulate cellular growth and division, as well as the regulation of nuclear transport within
`cells.
`
`Jonathan’s pro bono practice includes representing a mother in a child custody case in DC Superior Court.
`He represented a student in litigation related to the improper destruction of his home in DC Superior Court
`and US District Court for the District of Columbia.
`
`Jonathan serves as an adjunct professor at American University Washington College of Law, where he
`teaches a course on ANDA litigation and biosimilars litigation under BPCIA.
`
`Recent Representative Experience
`*representation prior to joining Cooley
`•
`
`BioDelivery Sciences International, Inc. v. Teva Pharmaceuticals USA Inc. and Teva
`Pharmaceutical Industries Ltd. (D. Del)
`Represented BDSI in Hatch-Waxman litigation concerning its Belbuca® product for the management
`of pain.
`
`•
`
`•
`
`BioDelivery Sciences International, Inc. v. Actavis Laboratires UT, Inc. and Actavis Inc. (D.
`Del)
`Represented BDSI in Hatch-Waxman litigation concerning its Bunavail® product for maintenance
`treatment of opioid dependence.
`
`United Therapeutics Corp. v. Liquidia Technologies
`Representing Liquidia in Hatch-Waxman litigation concerning Liquidia's 505(b)(2) NDA for inhaled
`powder treprostinil for the treatment of pulmonary arterial hypertension.
`
`Liquidia's Exhibit No. 1082
`Page 001
`
`

`

`•
`
`•
`
`•
`
`•
`
`•
`
`•
`
`•
`
`•
`
`Journey Medical Corp. and Rose U v. Perrigo
`Representing Journey Medical in a Hatch-Waxman litigation concerning
`Journey's Qbrexza® ((glycopyrronium cloth) product for the treatment of primary axillary
`hyperhidrosis) against ANDA filer Perrigo.
`
`Shire ViroPharma Inc. v. CSL Behring LLC*
`Representing defendant CSL Behring in patent litigation concerning its biologic Haegarda® for the
`prophylactic prevention of hereditary angioedema.
`
`AbbVie Inc. v. Boehringer Ingelheim International GmbH*
`Represented AbbVie in Biologics Price Competition and Innovation (BPCIA) litigation related to
`Humira®.
`
`Allergan/Forest Laboratories v. Sigmapharm Laboratories, LLC*
`Represented Forest Labs in ANDA litigation for its Saphris® (asenapine) product for the treatment of
`schizophrenia and bipolar disorder against multiple generic drug manufacturers.
`
`AbbVie Inc. and AbbVie Deutschland GmbH & Co. KG v. Hetero USA Inc. and Hetero Labs
`Ltd.*
`Represented AbbVie in ANDA litigation related to its Norvir® products for the treatment of HIV
`against multiple generic drug manufacturers in both the Southern District of Ohio and the District of
`Delaware.
`
`AbbVie Inc. v. Mylan Laboratories, Inc.*
`Represented AbbVie in ANDA litigation related to its Kaletra® products for the treatment of HIV
`against multiple generic drug manufacturers.
`
`Astellas US LLC v. Nycomed US Inc.*
`Represented Astellas in ANDA litigation related to its immunosuppressant drug Protopic®.
`
`Eli Lilly & Co. v. Wockhardt Ltd.*
`Represented Eli Lilly in ANDA litigation related to its Cymbalta® product against multiple generic drug
`manufacturers.
`
`Publications
`•
`•
`•
`
`"FDA Opens Useful Dialogue on Orange Book Patent Listings" Law 360 (June 2020). Co-Author.
`
`"Follow-On Biologics: Is Your Patent Portfolio Ready?" Law360 (March 2010). Co-Author.
`
`"Follow-On Biologics: A Patent Litigation Perspective" Pharmaceutical Commerce (August 2009).
`Co-Author.
`
`Education
`
`The Ohio State University, Moritz College of Law
`JD, 2008, magna cum laude
`
`The Ohio State University
`PhD, 2004, Molecular Genetics
`
`Pennsylvania State University
`MS, 1999, Physiology
`
`Grove City College
`BS, 1997, Biology
`
`Liquidia's Exhibit No. 1082
`Page 002
`
`

`

`Admissions & Credentials
`
`District of Columbia
`
`Maryland
`
`Court Admissions
`
`U.S. Court of Appeals, Federal Circuit
`
`Memberships
`
`American Intellectual Property Law Association
`
`Order of the Coif
`
`Liquidia's Exhibit No. 1082
`Page 003
`
`